Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand

被引:57
作者
Colls, BM
Harvey, VJ
Skelton, L
Frampton, CMA
Thompson, PI
Bennett, M
Perez, DJ
Dady, PJ
Forgeson, GV
Kennedy, ICS
机构
[1] Christchurch Hosp, Oncol Serv, Christchurch, New Zealand
[2] Auckland Hosp, Oncol Serv, Auckland, New Zealand
[3] Dunedin Hosp, Oncol Serv, Dunedin, New Zealand
[4] Wellington Hosp, Oncol Serv, Wellington, New Zealand
[5] Palmerston N Hosp, Oncol Serv, Palmerston North, New Zealand
[6] Waikato Hosp, Hamilton, New Zealand
关键词
stage I nonseminoma; testicular cancer; surveillance; long-term follow-up; orchidectomy;
D O I
10.1046/j.1464-410X.1999.00869.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective To re-evaluate a national prospective study in New Zealand after 17 years to define whether orchidectomy alone and surveillance for nonseminoma germ cell testicular tumour (NSGCTT) is a sound policy and matches the results achieved by other treatment protocols, Patients and Methods Between 1980 and 1997. 248 men with stage I NSGCTT, from six New Zealand centres, were managed by orchidectomy alone and surveillance. with treatment of relapses using combination chemotherapy. Results Seventy of the 248 patients (28%) relapsed: 42 of 92 (46%) with vascular and/or lymphatic invasion (VLI) in the primary tumour relapsed, whereas only 26 of 151 (17%) without this feature relapsed (P<0.001). VLI was the only identifiable risk factor for relapse in this series, Only one relapse occurred >28 months after orchidectomy, Despite poor compliance in some patients (12%) their survival was not prejudiced. Three patients died from disease despite chemotherapy at relapse. Al I; years and a median follow-up of 53 months, 242 of the 248 men are disease-free and the disease-specific survival rate is 98%. Conclusions This study shows that orchidectomy alone and treatment of relapses produces excellent longterm results without the adverse effects associated with retroperitoneal node dissection or elective chemotherapy for high-risk cases.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 24 条
  • [1] LATE RELAPSE OF TESTICULAR CANCER
    BANIEL, J
    FOSTER, RS
    GONIN, R
    MESSEMER, JE
    DONOHUE, JP
    EINHORN, LH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) : 1170 - 1176
  • [2] SELECTED EXPERIENCE WITH SURGERY AND COMBINATION CHEMOTHERAPY IN THE TREATMENT OF NONSEMINOMATOUS TESTIS TUMORS
    BREDAEL, JJ
    VUGRIN, D
    WHITMORE, WF
    SKINNER, DG
    [J]. JOURNAL OF UROLOGY, 1983, 129 (05) : 985 - 988
  • [3] RESULTS OF THE SURVEILLANCE POLICY OF STAGE-I NONSEMINOMATOUS GERM-CELL TESTICULAR-TUMORS
    COLLS, BM
    HARVEY, VJ
    SKELTON, L
    THOMPSON, PI
    DADY, PJ
    FORGESON, GV
    PEREZ, DJ
    [J]. BRITISH JOURNAL OF UROLOGY, 1992, 70 (04): : 423 - 428
  • [4] Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: A medical research council report
    Cullen, MH
    Stenning, SP
    Parkinson, MC
    Fossa, SD
    Kaye, SB
    Horwich, AH
    Harland, SJ
    Williams, MV
    Jakes, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) : 1106 - 1113
  • [5] TREATMENT OPTIONS IN CLINICAL STAGE-I NONSEMINOMATOUS GERM-CELL TUMORS OF THE TESTIS - A WAGER ON THE FUTURE - A REVIEW
    DROZ, JP
    VANOOSTEROM, AT
    [J]. EUROPEAN JOURNAL OF CANCER, 1993, 29A (07) : 1038 - 1044
  • [6] FREEDMAN LS, 1987, LANCET, V2, P294
  • [7] DETECTION OF RECURRENCE IN PATIENTS WITH CLINICAL STAGE-I NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS AND CONSEQUENCES FOR FURTHER FOLLOW-UP - A SINGLE-CENTER 10-YEAR EXPERIENCE
    GELS, ME
    HOEKSTRA, HJ
    SLEIJFER, DT
    MARRINK, J
    DEBRUIJN, HWA
    MOLENAAR, WM
    FRELING, NJM
    DROSTE, JHJ
    KOOPS, HS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) : 1188 - 1194
  • [8] CURRENT ISSUES IN THE MANAGEMENT OF CLINICAL STAGE-I TESTICULAR TERATOMA
    HORWICH, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1993, 29A (07) : 933 - 934
  • [9] RECURRENCE OF A NONSEMINOMATOUS GERM-CELL TUMOR 9 YEARS POSTOPERATIVELY - IS SURVEILLANCE ALONE ACCEPTABLE
    HURLEY, LJ
    LIBERTINO, JA
    [J]. JOURNAL OF UROLOGY, 1995, 153 (03) : 1060 - 1062
  • [10] Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer
    Klepp, O
    Dahl, O
    Flodgren, P
    Stierner, U
    Olsson, AM
    Oldbring, J
    Nilsson, S
    Daehlin, L
    Tornblom, M
    Smaland, R
    Starkhammar, H
    Abramsson, L
    Wist, E
    Raabe, N
    Edekling, T
    CavallinStahl, E
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (07) : 1038 - 1044